Revision Bioimplants Market Global Report 2026

The revision bioimplants market size has grown strongly in recent years. It will grow from $3.05 billion in 2025 to $3.33 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing incidence of implant failure and loosening, rising volume of joint replacement procedures, growing prevalence of age-related orthopedic disorders, expansion of reconstructive and corrective surgeries, and increased awareness of advanced revision treatment options.

The revision bioimplants market size is expected to see strong growth in the next few years. It will grow to $4.76 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth during the forecast period can be linked to increasing demand for long-lasting revision implant solutions, continuous advancements in biocompatible implant materials, rising adoption of minimally invasive revision surgical procedures, growing healthcare expenditure on complex surgical interventions, and expansion of the patient population requiring secondary implant surgeries. Key trends expected in the forecast period include greater adoption of revision-specific bioimplant designs, rising demand for durable and wear-resistant implant systems, increasing use of patient-matched implants in corrective surgeries, expansion of advanced biomaterial applications in revision procedures, and stronger focus on infection-resistant implant technologies.

The increasing incidence of chronic and degenerative disorders is expected to drive the growth of the revision bioimplants market going forward. Chronic and degenerative disorders refer to long-term progressive medical conditions such as cardiovascular diseases, osteoarthritis, osteoporosis, and spinal disorders that gradually impair body structure and organ function over time. The rising prevalence of chronic and degenerative disorders is increasing due to the expanding elderly population, which is at a higher risk of cardiovascular complications, tissue degeneration, and implant failure. Revision bioimplants assist in the treatment of chronic and degenerative disorders by replacing failed implants, restoring physiological function, and enhancing long-term patient outcomes. For instance, in January 2026, according to the American Heart Association, a US-based nonprofit cardiovascular health organization, cardiovascular disease caused 915,973 deaths in the United States in 2023, compared to 941,652 deaths in 2022, while coronary heart disease accounted for 349,470 deaths in 2023 compared to 371,506 deaths in 2022. Therefore, the increasing incidence of chronic and degenerative disorders is driving the growth of the revision bioimplants market.

Key companies operating in the revision bioimplants market are focusing on the adoption of personalized and 3D-printed revision implants, such as manufacturing patient-specific orthopedic implants, to improve anatomical fit, enhance implant stability, and reduce surgical complications. Manufacturing in the revision bioimplants market refers to the process of designing and producing customized implants using advanced technologies such as 3D printing and digital imaging to match individual patient anatomy and complex bone defects. For example, in February 2024, Smith+Nephew, a UK-based medical technology company, launched the AETOS Shoulder System for shoulder arthroplasty procedures. The system features a platform shoulder design with personalized implant positioning, 3D pre-operative planning capabilities, and augmented glenoid technology that supports precise implant placement and improved fixation in complex revision surgeries. The launch strengthens the adoption of patient-specific and digitally enabled implant solutions across the revision bioimplants market.

In May 2023, Zimmer Biomet Holdings, Inc., a US-based company specializing in musculoskeletal healthcare solutions, orthopedic implants, and robotic-assisted surgical technologies, acquired OSSIS for an undisclosed value. Through this acquisition, Zimmer Biomet intended to enhance its revision biologics and implant portfolio by broadening its expertise in patient-specific 3D-printed orthopedic implants and improving offerings for complex revision hip reconstruction procedures, tumor-related cases, and trauma surgeries. OSSIS is a New Zealand-based company that develops patient-specific 3D-printed titanium implants and orthopedic reconstruction solutions tailored for complex revision surgeries and customized bone replacement needs.

Major companies operating in the revision bioimplants market are Johnson & Johnson, Stryker Corporation, Zimmer Biomet Holdings Inc., Medtronic plc, Smith & Nephew plc, Globus Medical Inc., B. Braun Melsungen AG, Straumann Holding AG, Enovis Corporation, Integra LifeSciences Holdings Corporation, W. L. Gore & Associates Inc., Orthofix Medical Inc., MicroPort Scientific Corporation, Corbion N.V., LifeNet Health Inc., Cook Medical LLC, DSM Biomedical B.V., Exactech Inc., Invibio Ltd., Paragon 28 Inc., Peter Brehm GmbH, Maxx Orthopedics Inc., Implants International Ltd.

North America was the dominant region in the revision bioimplants market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in revision bioimplants report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the revision bioimplants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The revision bioimplants consists of sales of revision joint implants, revision knee implants, revision hip implants, spinal revision implants, dental revision implants, trauma fixation implants, bone graft substitutes, bioresorbable implants, and surgical meshes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The revision bioimplants market research report is one of a series of new reports that provides revision bioimplants market statistics, including revision bioimplants industry global market size, regional shares, competitors with a revision bioimplants market share, detailed revision bioimplants market segments, market trends and opportunities, and any further data you may need to thrive in the revision bioimplants industry. This revision bioimplants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.